Katja[a]
Antisense Pharma Presents AP 12009 Brain Cancer Studies At European Association for Neuro-Oncology Meeting (EANO)
REGENSBURG, GERMANY September 6, 2002. Antisense Pharma GmbH reports that results of a phase I/II clinical study investigating theuse of AP 12009 in patients with the most aggressive primary braintumor, high-grade glioma, showed excellent safety and tolerability.Surpassing the primary endpoint of the study, first efficacy data wereobtained. The observed effects on the tumor including remission are aclinical proof of concept of an immune activation by AP 12009. Bothpreclinical and clinical results will be presented on September 10that the Fifth Congress of the European Association for Neuro-Oncology(EANO) in Florence, Italy.
Presentations:
1. ANTISENSE OLIGONUCLEOTIDE AP 12009 SPECIFIC FOR mRNA ENCODING HUMANTRANSformING GROWTH FACTOR BETA2 (TGF-BETA2) IN THE THERAPY OFMALIGNANT GLIOMAS IN VITRO. Jachimczak P, Schlingensiepen KH,Schlingensiepen R, Bischof A, Hafner M, Schiller W, Szyrach M, Graf K,Kielmanowicz M, Stauder G, Hau P, and Bogdahn U. Oral Presentation#206 , 12:15 a.m. , 10 Sep 2002.
2. RESULTS OF CLINICAL I/II DOSE ESCALATION STUDY USING THE TGF-BETA2ANTISENSE OLIGONUCLEOTIDE AP 12009 ADMINISTERED INTRATUMORALLY TOPATIENTS WITH HIGH-GRADE GLIOMA. Hau P, Bogdahn U, Steinbrecher A,Zellner A, Schulmeyer F, Brawanski A, Goldbrunner M, Kunst M, StauderG, Jachimczak P, Schlingensiepen KH, Schlingensiepen R. Poster #181,1:30 p.m., 10 Sep 2002.
3. RESULTS OF SAFETY PHARMACOLOGY AND TOXICOLOGICAL STUDIES WITH THETGF-BETA2 ANTISENSE OLIGONUCLEOTIDE AP 12009. Stauder G,Schlingensiepen KH, Goldbrunner M, Jachimczak P, Schulmeyer F, andSchlingensiepen R. Poster #399, 1:30 p.m., 10 Sep 2002.
4. EFFECTS OF TGF-BETA ANTISENSE OLIGONUCLEOTIDES ON GENE EXPRESSIONOF GLIOBLASTOMA CELLS. Nickl-Jockschat T, Apfel R, Glasbrenner E,Jachimczak P, Giegerich G, Bogdahn U. Poster #290, 1:30 p.m., 8 Sep2002.
Antisense Pharma¹s business objective is the research, drugdevelopment and commercialization of antisense therapeutics for thetreatment of cancer. The company applies its longstanding expertise inantisense and oncology in developing a portfolio of antisensecompounds to either license them out or commercialize by its own. Thecompany focuses specially, but not only, on the key anticancer target,transforming growth factor-beta (TGF-beta). In a variety of cancers,elevated levels of TGF-beta are correlated with malignancy,invasiveness, metastasis and poor clinical prognosis.